B. Biesma

发表

Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.

E. Adang, F. Wilschut, J. Timmer-Bonte, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.

E. Adang, G. Bootsma, F. Wilschut, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

18 fluoro-2-deoxyglucose positron emission tomography (PET) in the assessment of induction chemotherapy in stage IIIA-N2 NSCLC: a multi-center prospective study

K. Nackaerts, L. Mortelmans, A. Lammertsma, 2001 .

Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.

Otto S Hoekstra, Adriaan A Lammertsma, Johan Vansteenkiste, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.

E. Vellenga, N. Mulder, E. de Vries, 1991, Cancer research.

Pulmonary Resection for Metastases from Colorectal Cancer

P. V. van Schaik, K. Bosscha, B. Biesma, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial

H. Groen, V. Torri, U. Dafni, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Hyperhydration with cisplatin does not influence pemetrexed exposure

A. Dingemans, J. Aerts, J. Burgers, 2021, British journal of clinical pharmacology.

Toxicity of pemetrexed during renal impairment explained—Implications for safe treatment

J. Aerts, J. Burgers, R. Mathijssen, 2021, International journal of cancer.

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study

O. Hoekstra, E. Smit, J. Aerts, 2019, British journal of cancer.

The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.

O. Hoekstra, E. Smit, F. Schramel, 2003, Lung cancer.

A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941)

G. Giaccone, E. Smit, F. Schramel, 2005 .

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment

E. Smit, F. Schramel, P. Postmus, 2004, British Journal of Cancer.

University of Groningen A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment

J. Stigt, H. Groen, B. Biesma, 2004 .

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

G. Giaccone, P. V. Van Schil, E. Smit, 2007, Journal of the National Cancer Institute.

Pharmacotherapy for treatment of lung cancer in the elderly

E. Smit, B. Biesma, B. van Veggel, 2015, Expert opinion on pharmacotherapy.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Johan Vansteenkiste, G. Scagliotti, Keunchil Park, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

H. Groen, E. Smit, J. Schellens, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.

F. Schramel, P. Postmus, H. Smit, 2009, Lung cancer.

B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)

E. Duffield, A. Armour, D. Ferry, 2007 .

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.

H. Groen, J. Aerts, G. Bootsma, 2021, The Lancet. Respiratory medicine.

A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.

O. Dalesio, H. Groen, E. Smit, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Yan Sun, Li Zhang, John V Heymach, 2010, The Lancet. Oncology.

Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: a population-based study in the Netherlands.

J. Coebergh, M. Janssen-Heijnen, V. Lemmens, 2007, Critical reviews in oncology/hematology.

Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)

E. Smit, F. Schramel, P. Postmus, 2006, British Journal of Cancer.

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.

E. Smit, P. Postmus, H. Groen, 1998, British Journal of Cancer.

Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.

G. Giaccone, P. Postmus, R. Dziadziuszko, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.

G. Giaccone, P. Postmus, J. V. van Meerbeeck, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.

H. Groen, P. Postmus, J. V. van Putten, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel a nd C arboplatin i n t he T reatment of S mall-Cell L ung C ancer P atients R esistant to C yclophosphamide , D oxorubicin, a nd Etoposide: A N on-Cross-Resist ant S chedule

E. Smit, P. Postmus, B. Biesma, 1999 .

Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): PRS-03

C. Obasaju, G. Scagliotti, J. von Pawel, 2007 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Effects of hematopoietic growth factors on chemotherapy-induced myelosuppression.

E. D. de Vries, E. Vellenga, B. Biesma, 1992, Critical reviews in oncology/hematology.

Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer.

E. Smit, H. van Tinteren, H. Groen, 2007, European journal of cancer.

Recombinant human interleukin-3 administered concomitantly with chemotherapy in patients with relapsed small cell lung cancer.

P. Postmus, B. Biesma, K. V. van Kralingen, 2002, Journal of experimental therapeutics & oncology.

Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study.

E. Vellenga, E. de Vries, J. Gietema, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy

G. Giaccone, E. Smit, F. Schramel, 2001, British Journal of Cancer.

A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy.

E. Smit, P. Postmus, B. Biesma, 1999, Lung cancer.

Effects of interleukin-3 after chemotherapy for advanced ovarian cancer.

E. Vellenga, N. Mulder, E. de Vries, 1992, Blood.

Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.

N. Mulder, E. de Vries, B. Mull, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of interleukin-3 after chemotherapy for advanced ovarian cancer

de Elisabeth G. E. Vries, E. Vellenga, N. Mulder, 1992 .

The effects of five hematopoietic growth factors on human small cell lung carcinoma cell lines: interleukin 3 enhances the proliferation in one of the eleven cell lines.

C. Meyer, E. D. de Vries, E. Vellenga, 1991, Cancer research.

Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?

J. Bussink, D. de Ruysscher, G. Bootsma, 2016, Lung cancer.

Phase II study of induction chemotherapy in patients with stage IIIB NSCLC

F. Schramel, C. Pitz, P. Hofman, 2000 .

Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.

P. Postmus, D. Wagener, J. Festen, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever.

E. D. de Vries, P. Postmus, E. Vellenga, 1990, European journal of cancer.

Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy

de Elisabeth G. E. Vries, E. Vellenga, B. Biesma, 1991, The Lancet.

Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.

J. Aerts, G. Bootsma, P. Baas, 2020, EBioMedicine.

Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.

H. D. de Bruijn, N. Mulder, E. de Vries, 1992, British Journal of Cancer.

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975.

G. Giaccone, A. Bottomley, E. Smit, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors.

E. D. de Vries, I. Kema, F. Muskiet, 1994, Clinical chemistry.

Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.

A. Tafreshi, R. Govindan, Xin Huang, 2022, Clinical lung cancer.

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands

E. Schuuring, W. Dinjens, E. Speel, 2020 .

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity

E. Schuuring, W. Dinjens, E. Speel, 2020, Frontiers in Oncology.

International real-world study of DLL3 expression in patients with small cell lung cancer.

F. Rojo, F. Penault-Llorca, P. Pauwels, 2020, Lung cancer.

Phase III study comparing cyclophosphamide, doxorubicin, and etoposide (CDE) to carboplatin and paclitaxel (CP) in patients (pts) with extensive disease small cell lung cancer (ED SCLC).

E. Smit, H. Tinteren, H. Groen, 2005 .

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

G. Scagliotti, Keunchil Park, F. de Marinis, 2010, Lung cancer.

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.

E. Thunnissen, S. V. van Riel, D. Heideman, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

G. Giaccone, E. Smit, F. Schramel, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958).

G. Giaccone, E. Smit, M. Krzakowski, 2003, European Journal of Cancer.

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment

E. Smit, F. Schramel, P. Postmus, 2004, British Journal of Cancer.

Improvement in population‐based survival of stage IV NSCLC due to increased use of chemotherapy

J. Aerts, B. E. van den Borne, J. Kloover, 2015, International journal of cancer.

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

F. Schramel, A. Dingemans, B. Biesma, 2012, Health and Quality of Life Outcomes.

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

R. Govindan, H. Choy, T. Mok, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).

G. Giaccone, T. Gorlia, A. Ardizzoni, 2003, Annals of Oncology.

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.

F. Hirsch, E. Duffield, A. Armour, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute-phase response in patients given rhIL-3 after chemotherapy

P. Postmus, E. Vellenga, A. Khwaja, 1992, The Lancet.

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

A. Santoro, J. von Pawel, L. Paz-Ares, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.

O. Dalesio, H. Groen, J. Slaets, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact.

J. Aerts, V. Lemmens, B. E. van den Borne, 2015, Clinical lung cancer.

Pulmonary injury associated with spray of a water-based nano-sized waterproofing product: a case study

Peder Wolkoff, P. Scheepers, I. Koponen, 2017, Journal of Occupational Medicine and Toxicology.

COPD in cancer patients: higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient.

J. Coebergh, M. Janssen-Heijnen, L. V. van de Poll-Franse, 2007, European journal of cancer.

Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

O. Dalesio, H. Groen, F. Schramel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.

R. Ramlau, M. Krzakowski, A. Santoro, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.

N. Mulder, E. de Vries, J. Kovarik, 1993, Cancer research.

Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984).

G. Giaccone, J. V. van Meerbeeck, C. Legrand, 2006, European journal of cancer.

Cumulative pemetrexed dose increases the risk of nephrotoxicity.

M. M. van den Heuvel, L. Hilbrands, R. ter Heine, 2020, Lung cancer.

Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N 2 Non – Small-Cell Lung Cancer

G. Giaccone, E. Smit, F. Schramel, 2007 .

Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy.

G. Giaccone, P. V. Van Schil, E. Smit, 2006, European Journal of Cancer.

Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.

B. Biesma, C. Melissant, Paul R van de Werf, 2007, Lung cancer.

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.

Tuan S. Nguyen, K. Syrigos, F. Mayer, 2013, Lung cancer.

A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.

H. Groen, E. Smit, J. Aerts, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting short- and long-term outcome.

M. Janssen-Heijnen, B. Biesma, E. Veen, 2009, Interactive cardiovascular and thoracic surgery.

Institutional report - Pulmonary Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting short- and long-term outcome

B. Biesma, E. Veen, R. J. Bolhuis, 2009 .

Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial

H. Groen, A. Dingemans, F. Schramel, 2020, Frontiers in Oncology.

Randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small cell lung cancer patients: The NVALT-8 study.

H. Groen, E. Smit, F. Schramel, 2016 .

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.

E. Thunnissen, S. V. van Riel, D. Heideman, 2012 .

R. Govindan, H. Choy, T. Mok, 2016, Journal of Clinical Oncology.

Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial

A. Dingemans, J. Burgers, R. Mathijssen, 2022, Cancer Chemotherapy and Pharmacology.

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

G. Scagliotti, Keunchil Park, F. de Marinis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

University of Groningen Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain Brouns,

H. Groen, F. Schramel, A. Dingemans, 2020 .